Updated on 2025/03/27

写真a

 
ADACHI Shiro
 
Organization
Nagoya University Hospital Cardiology Assistant Professor
Graduate School
Graduate School of Medicine
Title
Assistant Professor
Profile
肺高血圧症診療および臨床研究を行っております。慢性血栓塞栓性肺高血圧症への肺動脈形成術(BPA)も積極的に行っております。
External link

Degree 1

  1. 博士(医学) ( 2016.3   名古屋大学 ) 

Education 1

  1. Nagoya University   Graduate School, Division of Medical Sciences

    2016.3

      More details

    Country: Japan

Professional Memberships 3

  1. 日本肺高血圧肺循環学会

  2. 日本内科学会

  3. 日本循環器学会

 

Papers 41

  1. A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial. Reviewed

    Hosokawa K, Watanabe H, Taniguchi Y, Ikeda N, Inami T, Yasuda S, Murohara T, Hatano M, Tamura Y, Yamashita J, Tatsumi K, Tsujino I, Kobayakawa Y, Adachi S, Yaoita N, Minatsuki S, Todaka K, Fukuda K, Tsutsui H, Abe K; KABUKI Investigators.

    Circulation   Vol. 149   page: 406 - 409   2024

     More details

    Language:English  

    DOI: 10.1161/CIRCULATIONAHA.123.067528

  2. Outcomes of Chronic Thromboembolic Pulmonary Hypertension After Balloon Pulmonary Angioplasty and Pulmonary Endarterectomy. Reviewed

    Masaki K, Hosokawa K, Funakoshi K, Taniguchi Y, Adachi S, Inami T, Yamashita J, Ogino H, Tsujino I, Hatano M, Yaoita N, Ikeda N, Shimokawahara H, Tanabe N, Kubota K, Shigeta A, Ogihara Y, Horimoto K, Dohi Y, Kawakami T, Tamura Y, Tatsumi K, Abe K; CTEPH AC Registry Study Group.

    JACC Asia   Vol. 4   page: 577 - 589   2024

     More details

    Language:English  

    DOI: 10.1016/j.jacasi.2024.05.007

  3. Insights into balloon pulmonary angioplasty and the WHO functional class of chronic thromboembolic pulmonary hypertension patients: findings from the CTEPH AC registry Reviewed

    Nobutaka Ikeda 1, Kohei Masaki 2, Kazuya Hosokawa 2, Kouta Funakoshi 3, Yu Taniguchi 4, Shiro Adachi 5, Takumi Inami 6, Jun Yamashita 7, Hitoshi Ogino 8, Ichizo Tsujino 9, Masaru Hatano 10, Nobuhiro Yaoita 11, Hiroto Shimokawahara 12, Nobuhiro Tanabe 13, Kayoko Kubota 14, Ayako Shigeta 15, Yoshito Ogihara 16, Koshin Horimoto 17, Yoshihiro Dohi 18, Takashi Kawakami 19, Yuichi Tamura 20, Koichiro Tatsumi 15, Kohtaro Abe 2

    Cardiovasc Interv Ther .     2025

     More details

    Language:English  

    DOI: 10.1007/s12928-025-01095-9

  4. Clinical usefulness of endothelial progenitor cells in predicting the efficacy of riociguat in chronic thromboembolic pulmonary hypertension Reviewed

    Ryo Imai 1 2, Shiro Adachi 3, Masahiro Yoshida 1, Shigetake Shimokata 1, Yoshihisa Nakano 3, Naoki Okumura 1, Toyoaki Murohara 1, Takahisa Kondo 1 2

    Nagoya J Med Sci   Vol. 14 ( 1 ) page: 25762   2024

     More details

    Language:English  

    DOI: 10.18999/nagjms.86.2.292

  5. Controlling Nutritional Status Score Predicts One-year Outcomes in Chronic Thromboembolic Pulmonary Hypertension Invited Reviewed

    Adachi, Takeshi; Adachi, Shiro; Nakano, Yoshihisa; Nishiyama, Itsumure; Miku, Hirose; Murohara, Toyoaki

    Circulation Report   Vol. 6 ( 9 ) page: 381 - 388   2024

     More details

    Authorship:Corresponding author  

    DOI: 10.1253/circrep.CR-24-0023

  6. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study) Invited Reviewed

    Yuichi Tamura 1, Hiraku Kumamaru 2, Ichizo Tsujino 3, Rika Suda 4, Kohtaro Abe 5, Takumi Inami 6, Koshin Horimoto 7, Shiro Adachi 8, Satoshi Yasuda 9, Fusako Sera 10, Yu Taniguchi 11, Masataka Kuwana 12 13, Koichiro Tatsumi 4; Japan Pulmonary Hypertension Registry Network

    Pharmaceuticals (Basel) .     2024

     More details

  7. Detrimental Impact of Comorbid Mental Disorders in Chronic Thromboembolic Pulmonary Hypertension - A Retrospective Observational Study Invited Reviewed

    Takeshi Adachi 1, Shiro Adachi 1, Yoshihisa Nakano 2, Kenichiro Yasuda 3, Itsumure Nishiyama 2, Miku Hirose 2, Toyoaki Murohara 1

    Circ Rep     2024

     More details

  8. Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors Reviewed

    Yoshihisa Nakano 1 2, Shiro Adachi 3, Miku Hirose 4, Takeshi Adachi 2, Itsumure Nishiyama 4, Kenichiro Yasuda 2 5, Masahiro Yoshida 4 6, Takahisa Kondo 4 7, Toyoaki Murohara 4

    Sci Rep .   Vol. 14 ( 1 ) page: 25762   2024

     More details

    Authorship:Corresponding author   Language:English  

    DOI: 10.1038/s41598-024-74481-7

  9. Long-term outcome of chronic thromboembolic pulmonary hypertension using direct oral anticoagulants and warfarin: a Japanese prospective cohort study Reviewed

    Kazuya Hosokawa 1, Kohtaro Abe 2, Kouta Funakoshi 3, Yuichi Tamura 4, Naoki Nakashima 5, Koji Todaka 3, Yu Taniguchi 6, Takumi Inami 7, Shiro Adachi 8, Ichizo Tsujino 9, Jun Yamashita 10, Shun Minatsuki 11, Nobutaka Ikeda 12, Hiroto Shimokawahara 13, Takashi Kawakami 14, Takeshi Ogo 15, Masaru Hatano 11, Hitoshi Ogino 16, Yoshihiro Fukumoto 17, Nobuhiro Tanabe 18, Hiromi Matsubara 13, Keiichi Fukuda 19, Koichiro Tatsumi 20, Hiroyuki Tsutsui 2

    J Thromb Haemost   Vol. 8   page: 2151 - 2162   2023

     More details

    Authorship:Corresponding author   Language:English  

    DOI: 10.1016/j.jtha.2023.03.036

  10. SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol Reviewed

    Yuichi Tamura 1 2, Rika Takeyasu 1, Tomohiro Takata 3, Naoki Miyazaki 4, Ryo Takemura 4, Michihiko Wada 4, Yudai Tamura 1 2, Kohtaro Abe 5, Ayako Shigeta 6, Yu Taniguchi 7, Shiro Adachi 8, Takumi Inami 9, Ichizo Tsujino 10, Nobuhiro Tahara 11, Masataka Kuwana 12

    Pulm Circ .   Vol. 13 ( 2 )   2023

     More details

    Language:English  

    DOI: 10.1002/pul2.12251.

  11. Right ventricular pressure overload related to residual thrombotic burden in patients 1 year after acute pulmonary embolism: From the Nagoya PE study

    Nakano Yoshihisa, Adachi Shiro, Nishiyama Itsumure, Yasuda Kenichiro, Yoshida Masahiro, Iwano Shingo, Kondo Takahisa, Murohara Toyoaki

    THROMBOSIS RESEARCH   Vol. 216   page: 113 - 119   2022.8

     More details

  12. Safe and successful transition from oral selexipag to subcutaneous treprostinil in a patient with idiopathic pulmonary arterial hypertension treated with triple combination therapy.

    Adachi S, Nishiyama I, Yasuda K, Yoshida M, Nakano Y, Kondo T, Murohara T

    Journal of cardiology cases   Vol. 26 ( 1 ) page: 42 - 45   2022.7

     More details

    Language:English  

    DOI: 10.1016/j.jccase.2022.02.003

    PubMed

  13. Right Ventricular Dyssynchrony Casts New Light on the Risk Stratification and Prediction of Prognosis in Patients With Pulmonary Hypertension

    Adachi Shiro, Nakano Yoshihisa, Furusawa Kenji

    CIRCULATION JOURNAL   Vol. 86 ( 6 ) page: 945 - 946   2022.6

     More details

  14. Implications of Pulmonary Artery Wave Reflection in Patients With Pulmonary Hypertension

    Nakano Yoshihisa, Adachi Shiro

    CIRCULATION JOURNAL   Vol. 86 ( 6 ) page: 956 - 957   2022.6

     More details

  15. Usefulness of a refined computed tomography imaging method to assess the prevalence of residual pulmonary thrombi in patients 1 year after acute pulmonary embolism: The Nagoya PE study

    Nakano Yoshihisa, Adachi Shiro, Nishiyama Itsumure, Yasuda Kenichiro, Imai Ryo, Yoshida Masahiro, Iwano Shingo, Kondo Takahisa, Murohara Toyoaki

    JOURNAL OF THROMBOSIS AND HAEMOSTASIS   Vol. 20 ( 4 ) page: 888 - 898   2022.4

     More details

  16. Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy

    Yasuda Kenichiro, Adachi Shiro, Nishiyama Itsumure, Yoshida Masahiro, Nakano Yoshihisa, Murohara Toyoaki

    PULMONARY CIRCULATION   Vol. 12 ( 2 ) page: e12074   2022.4

     More details

  17. End-Systolic Eccentricity Index Obtained by Enhanced Computed Tomography Is a Predictor of Pulmonary Vascular Resistance in Patients with Chronic Thromboembolic Pulmonary Hypertension

    Tsutsumi Yoshinori, Adachi Shiro, Nakano Yoshihisa, Iwano Shingo, Abe Shinji, Kato Katsuhiko, Naganawa Shinji

    LIFE-BASEL   Vol. 12 ( 4 )   2022.4

     More details

  18. Pulmonary tumor thrombotic microangiopathy with thrombus in pulmonary artery caused by diffuse sclerosing variant of thyroid papillary adenocarcinoma: A case report

    Yoshida Masahiro, Adachi Shiro, Nishiyama Itsumure, Yasuda Kenichiro, Imai Ryo, Nakano Yoshihisa, Tsuyuki Yuta, Kim Deoksu, Kondo Takahisa, Murohara Toyoaki

    PULMONARY CIRCULATION   Vol. 12 ( 1 ) page: e12027   2022.1

     More details

  19. Left Upper Lobe Trisegmentectomy After Pulmonary Endarterectomy

    Tsubouchi Hideki, Goto Masaki, Terazawa Sachie, Adachi Shiro, Suzuki Yuka, Usui Akihiko, Kondo Takahisa, Chen-Yoshikawa Toyofumi F.

    ANNALS OF THORACIC SURGERY   Vol. 112 ( 5 ) page: E361 - E363   2021.11

     More details

  20. Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population

    Yoshida Masahiro, Adachi Shiro, Imai Ryo, Shimokata Shigetake, Nakano Yoshihisa, Murohara Toyoaki, Kondo Takahisa

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 83 ( 2 ) page: 321 - 330   2021.5

     More details

  21. Mortality, Recurrent Thromboembolism and Major Bleeding in Cancer-Associated and Non-Cancer Pulmonary Embolism Patients Treated With Direct Oral Anticoagulants.

    Nakano Y, Adachi S, Imai R, Yoshida M, Shimokata S, Murohara T, Kondo T

    Circulation journal : official journal of the Japanese Circulation Society     2021.4

     More details

    Language:English  

    DOI: 10.1253/circj.CJ-20-1247

    PubMed

  22. Endostatin and Vascular Endothelial Growth Factor-A<sub>165</sub>b May Contribute to Classification of Pulmonary Hypertension.

    Adachi S, Kikuchi R, Shimokata S, Suzuki A, Yoshida M, Imai R, Nakano Y, Kondo T, Murohara T

    Circulation reports   Vol. 3 ( 3 ) page: 161 - 169   2021.2

     More details

    Language:English  

    DOI: 10.1253/circrep.CR-20-0096

    PubMed

  23. Clinical course of pulmonary embolism patients treated with DOACs: comparing prognosis, recurrent thromboembolism, and major bleeding between patients with and without cancer

    Nakano Y., Imai R., Yoshida M., Shimokata S., Adachi S., Murohara T., Kondo T.

    EUROPEAN HEART JOURNAL   Vol. 41   page: 2279 - 2279   2020.11

     More details

    Language:Japanese  

    Web of Science

  24. Potential of Selexipag in Chronic Thromboembolic Pulmonary Hypertension Medical Therapy

    Kondo Takahisa, Nakano Yoshihisa, Adachi Shiro

    CIRCULATION JOURNAL   Vol. 84 ( 10 ) page: 1691 - 1692   2020.10

     More details

  25. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan

    Imai Ryo, Adachi Shiro, Yoshida Masahiro, Shimokata Shigetake, Nakano Yoshihisa, Okumura Naoki, Murohara Toyoaki, Kondo Takahisa

    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY   Vol. 98 ( 9 ) page: 653 - 658   2020.9

     More details

    Language:Japanese  

    Web of Science

  26. Single-center prognostic validation of the risk assessment of the 2015 ESC/ERS guidelines in patients with pulmonary arterial hypertension in Japan.

    Imai R, Adachi S, Yoshida M, Shimokata S, Nakano Y, Okumura N, Murohara T, Kondo T

    Canadian journal of physiology and pharmacology   Vol. 98 ( 9 ) page: 653 - 658   2020.9

     More details

    Language:English  

    DOI: 10.1139/cjpp-2019-0640

    PubMed

  27. Risk of Pulmonary Arterial Hypertension During Qing-Dai Use for the Treatment of Ulcerative Colitis

    Adachi Shiro, Nakano Yoshihisa, Kondo Takahisa

    CIRCULATION JOURNAL   Vol. 84 ( 8 ) page: 1235 - 1236   2020.8

     More details

  28. Automatic Remasking of Digital Subtraction Angiography Images in Pulmonary Angiography

    Mizukuchi Takashi, Uemura Takeshi, Kondo Satoru, Abe Shinji, Adachi Shiro, Okumura Naoki, Kondo Takahisa, Koyama Shuji

    JOURNAL OF DIGITAL IMAGING   Vol. 33 ( 2 ) page: 531 - 537   2020.4

     More details

  29. Addition of a bilateral access form of peripheral extracorporeal membrane oxygenation rescued a patient with idiopathic pulmonary arterial hypertension who developed circulatory collapse immediately after childbirth

    Adachi Shiro, Shimokata Shigetake, Yoshida Masahiro, Imai Ryo, Nakano Yoshihisa, Okumura Naoki, Suzuki Susumu, Murohara Toyoaki, Kondo Takahisa

    PULMONARY CIRCULATION   Vol. 10 ( 1 ) page: 2045894020910140   2020.1

     More details

  30. Assessment of Severity in Chronic Thromboembolic Pulmonary Hypertension by Quantitative Parameters of Dual-Energy Computed Tomography

    Tsutsumi Yoshinori, Iwano Shingo, Okumura Naoki, Adachi Shiro, Abe Shinji, Kondo Takahisa, Kato Katsuhiko, Naganawa Shinji

    JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY   Vol. 44 ( 4 ) page: 578 - 585   2020

     More details

  31. Effects of Tobacco Smoking on Cardiovascular Disease

    Kondo Takahisa, Nakano Yoshihisa, Adachi Shiro, Murohara Toyoaki

    CIRCULATION JOURNAL   Vol. 83 ( 10 ) page: 1980 - 1985   2019.10

     More details

  32. Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity

    Hirashiki Akihiro, Adachi Shiro, Okumura Naoki, Nakano Yoshihisa, Shimokata Shigetake, Shimizu Atsuya, Arai Hidenori, Toba Kenji, Murohara Toyoaki, Kondo Takahisa

    HEALTH AND QUALITY OF LIFE OUTCOMES   Vol. 17 ( 1 ) page: 103   2019.6

     More details

  33. Goal-Oriented Sequential Combination Therapy Evaluated Using Cardiopulmonary Exercise Parameters for the Treatment of Newly Diagnosed Pulmonary Arterial Hypertension - Goal-Oriented Therapy Evaluated by Cardiopulmonary Exercise Testing for Pulmonary Arterial Hypertension (GOOD EYE).

    Hirashiki A, Kondo T, Adachi S, Nakano Y, Kamimura Y, Shimokata S, Okumura N, Shimizu A, Washimi Y, Arai H, Murohara T, GOOD EYE Investigators.

    Circulation reports   Vol. 1 ( 7 ) page: 303 - 311   2019.6

     More details

    Language:English  

    DOI: 10.1253/circrep.CR-19-0047

    PubMed

  34. Renin Activity as a Key Predictor of Major Adverse Cardiac Events

    Kondo Takahisa, Nakano Yoshihisa, Adachi Shiro, Murohara Toyoaki

    CIRCULATION JOURNAL   Vol. 83 ( 6 ) page: 1204 - 1205   2019.6

     More details

  35. Pulmonary Hypertension: Diagnosis, Management, and Treatment

    Kondo Takahisa, Okumura Naoki, Adachi Shiro, Murohara Toyoaki

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 1 ) page: 19 - 30   2019.2

     More details

  36. Usefulness of scoring right ventricular function for assessment of prognostic factors in patients with chronic thromboembolic pulmonary hypertension

    Kamimura Yoshihiro, Okumura Naoki, Adachi Shiro, Shimokata Shigetake, Tajima Fumitaka, Nakano Yoshihisa, Hirashiki Akihiro, Murohara Toyoaki, Kondo Takahisa

    HEART AND VESSELS   Vol. 33 ( 10 ) page: 1220 - 1228   2018.10

     More details

  37. Left ventricular end-diastolic dimension and septal e' are predictors of cardiac index at rest, while tricuspid annular plane systolic excursion is a predictor of peak oxygen uptake in patients with pulmonary hypertension

    Nakano Yoshihisa, Okumura Naoki, Adachi Shiro, Shimokata Shigetake, Tajima Fumitaka, Kamimura Yoshihiro, Murohara Toyoaki, Kondo Takahisa

    HEART AND VESSELS   Vol. 33 ( 5 ) page: 521 - 528   2018.5

     More details

  38. Left ventricular end-diastolic dimension, septal e prime and tricuspid annular plane systolic excursion are useful for evaluating conditions of patients with pulmonary hypertension

    Nakano Y., Okumura N., Adachi S., Shimokata S., Kamimura Y., Tajima F., Murohara T., Kondo T.

    EUROPEAN HEART JOURNAL   Vol. 38   page: 1151 - 1151   2017.8

     More details

    Language:Japanese  

    Web of Science

  39. Effects of balloon pulmonary angioplasty were modest in patients with inoperable central-type chronic thromboembolic pulmonary hypertension

    Adachi S., Okumura N., Tajima F., Shimokata S., Kamimura Y., Nakano Y., Murohara T., Kondo T.

    EUROPEAN HEART JOURNAL   Vol. 38   page: 1079 - 1080   2017.8

     More details

    Language:Japanese  

    Web of Science

  40. Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension

    Hirashiki Akihiro, Adachi Shiro, Nakano Yoshihisa, Kamimura Yoshihiro, Shimokata Shigetake, Takeshita Kyosuke, Shimizu Atsuya, Toba Kenji, Murohara Toyoaki, Kondo Takahisa

    PULMONARY CIRCULATION   Vol. 7 ( 2 ) page: 448 - 454   2017

     More details

  41. Left main coronary artery compression by a dilated main pulmonary artery and left coronary sinus of Valsalva aneurysm in a patient with heritable pulmonary arterial hypertension and FLNA mutation

    Hirashiki Akihiro, Adachi Shiro, Nakano Yoshihisa, Kamimura Yoshihiro, Ogo Takeshi, Nakanishi Norifumi, Morisaki Takayuki, Morisaki Hiroko, Shimizu Atsuya, Toba Kenji, Murohara Toyoaki, Kondo Takahisa

    PULMONARY CIRCULATION   Vol. 7 ( 3 ) page: 734 - 740   2017

     More details

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. 肺細動脈内皮細胞で特徴的変化を示す分子に着目した肺高血圧症への新規治療戦略の開発

    Grant number:22K08123  2022.4 - 2025.3

    科学研究費助成事業  基盤研究(C)

    加藤 勝洋, 足立 史郎, 室原 豊明

      More details

    Authorship:Coinvestigator(s) 

    肺動脈性肺高血圧症(PAH)は指定難病の1つであり、肺血管拡張薬の開発により患者の短期予後は以前より改善したものの、治療が奏功しない症例も多く、新規治療薬および診断バイオマーカーの開発が急務である。PAHにおいて、なぜ全身の血管ではなく、末梢側の肺細動脈のみで異常をきたすのかは解っていない。本研究では、全身の動脈と比較して、肺細動脈で特徴的な発現変動を示す分子に着目し、培養細胞、個体、患者臨床検体と組み合わせて、病態を解き明かす。本研究によって、PAHの病理の具体的発症メカニズムの理解を深め、新規治療戦略をもたらすことができる。
    肺高血圧症は、全身の血管網ではなく主病変部である肺細動脈局所のシグナル異常が発端とした疾患であることが予測され、現在までに行なった網羅的スクリーニングの結果、肺細動脈内皮細胞特異的に発現する分子A、分子Bを見出してきた。これらの分子の解析を通して、肺高血圧症の疾患制御機構の解明や創薬を含む治療戦略の開発、早期診断のためのバイオマーカーの開発につなげることを目的としている。現時点で以下のような実験の結果を得ている。
    1、培養肺動脈内皮細胞を用いて分子A及び分子BをsiRNAを用いたノックダウンやレンチウイルスを用いた過剰発現を行い、BMP/TGF-β/Smad、MAPキナーゼ、PI3K/Aktなどの細胞内シグナルの検証を行なっている。また、低酸素曝露した際の分子A及び分子Bの発現変化について検証し、分子Bに関しては発現の低下を認めた。
    2、分子Aまたは分子Bに対する遺伝子欠損マウスの作成を進めた。分子Aに対する遺伝子欠損マウスに関して、解析を進めているが現時点では有意な変化を認めていない。分子Aまたは分子Bをマウス個体で過剰発現させるためのアデノ随伴ウイルスの作成を進め、分子Aの過剰発現に関しては有意な変化を認めなかった。
    3、肺高血圧症の病態解明およびバイオマーカーの可能性を検証するために、肺高血圧症患者に対して右心カテーテル検査を実施する際に血液検体の採取を行なっている。肺動脈の前後で血中濃度を比較検討するために、肺動脈と左心室より血液検体の採取・保存している。現在までに101人の肺高血圧症患者より血液検体の採取を完了した。分子Aに関して、13症例の検体で測定を行い、平均肺動脈圧と混合静脈血酸素飽和濃度と相関の可能性が示唆された。
    本年度は、培養肺動脈内皮細胞を用いた分子A及び分子Bの機能について評価を進めている。さらに個体での遺伝子の影響を評価するために、分子Aまたは分子Bに対する遺伝子欠損マウスの開発を進めており、分子Aに関しては解析も進んでいる。また、肺高血圧患者血液検体の収集、解析も進めており、これらの到達度は当初の研究計画の予定を考えると順調であると考えられる。
    引き続き、培養肺動脈内皮細胞を用いて分子A及び分子Bを中心とした細胞内シグナル伝達への修飾作用について評価を進めるとともに平滑筋細胞や線維芽細胞への影響を評価する。作製した遺伝子欠損マウスの個体での解析を進める。収集した肺高血圧症患者の血液検体の解析を進める。

  2. Severity index of chronic thromboembolic pulmonary hypertension

    Grant number:20K17075  2020.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    Adachi Shiro

      More details

    Authorship:Principal investigator 

    Grant amount:\2600000 ( Direct Cost: \2000000 、 Indirect Cost:\600000 )

    The refined CT imaging method made it easier to see the thrombus in the periphery of the pulmonary artery, it was found that the residual thrombus after acute pulmonary embolism was 74%. It was found that the residual thrombus 1 month after acute pulmonary embolism is a risk factor, and it is important to follow up carefully for the group of patients with residual thrombus. The transition to chronic thromboembolic pulmonary hypertension (CTEPH) was 3.8%. Furthermore, although the amount of thrombus at the time of diagnosis of CTEPH is not related to the severity, it was found to be useful for determining the therapeutic effect of pulmonary vasodilators and catheter treatment. In addition, low thrombus volume may indicate relatively advanced pulmonary artery degeneration, suggesting that pulmonary vasodilators are more useful than catheterization in such groups.

  3. Role of VEGF165b, an inhibitory vascular endothelial growth factor splice variant, in pulmonary hypertension

    Grant number:17K09551  2017.4 - 2020.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Kondo Takahisa

      More details

    Authorship:Coinvestigator(s) 

    Pulmonary hypertension (PH) is a pathophysiological disorder that involves dysregulated proliferation of pulmonary arterial endothelial cells and of smooth muscle cells, resulting in an increase in pulmonary vascular resistance, right-sided heart failure and death. In patients with advanced PH, dysfunctional angiogenesis is one of the main mechanisms of disease progression. Therefore, understanding the balance between angiogenic and antiangiogenic factors is important. In the present study, Role of VEGF165b, an inhibitory vascular endothelial growth factor splice variant, were investigated. In lung disease associated PH (LD-PH), serum levels of VEGF165b were elevated. Among patients with pulmonary arterial hypertension (PAH), serum levels of VEGF165b were elevated in PAH associated with connective tissue disease. VEGF165b may be involved in the pathophysiological disorder of LD-PH and PAH associated with connective tissue disease.

  4. The role of VEGF in pulmonary hypertension

    Grant number:17K15997  2017.4 - 2019.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    Adachi Shiro, Murohara Toyoaki, Kondo Takahisa, Nakano Yoshihisa, Kikuchi Ryosuke, Shimokata Shigetake

      More details

    Authorship:Principal investigator 

    Grant amount:\2600000 ( Direct Cost: \2000000 、 Indirect Cost:\600000 )

    Pulmonary hypertension is severe condition with stenosis of pulmonary artery leading to lethal heart failure. VEGF has a potential relating to this stenosis, obstruction. Therefore, the aim of this study was to clarify roles of VEGF-A and VEGF-A165b on pulmonary hypertension. VEGF-165 and VEGF-165b were significantly increased in patients with pulmonary hypertension compared to control. in the sub-analysis that verified the difference among etiology of pulmonary hypertension, VEGF-A and VEGF-165b were significantly increased in chronic thromboembolic pulmonary hypertension and connective tissue disease associated pulmonary hypertension compared to other etiologies. VEGF-A and 165b was useful